Stockguru
  • Home
  • Stock Market
  • Business
  • Econonmy
  • Investment
No Result
View All Result
Get Started
  • Home
  • Stock Market
  • Business
  • Econonmy
  • Investment
No Result
View All Result
Stockguru
No Result
View All Result
Pacific Biosciences gains on TD Cowen upgrade, citing potential for sales growth By Investing.com

Pacific Biosciences gains on TD Cowen upgrade, citing potential for sales growth By Investing.com

admin by admin
March 31, 2023
in Econonmy
0
Share on FacebookShare on Twitter

You might also like

UK regulator says it may clear Microsoft’s new Activision Blizzard takeover offer

UK regulator says it may clear Microsoft’s new Activision Blizzard takeover offer

September 22, 2023
Nio launches high-end smartphone for use with electric cars

Nio launches high-end smartphone for use with electric cars

September 21, 2023


Pacific Biosciences gains on TD Cowen upgrade, citing potential for sales growth
© Reuters.

By Liz Moyer

Investing.com — Pacific Biosciences (NASDAQ:) shares have been rising after TD Cowen referred to as the corporate a development transformation story.

Shares have been up 16% on Friday, and are up 38% thus far this yr. TD Cowen raised its score to Outperform from Market Carry out and raised its value goal to $15 from $13. At Thursday’s closing value of $9.76, the brand new value goal implies a 53% upside.

“Choosing the right entry level might be tough, however we expect it’s time to get on board this multi-year story,” TD Cowen analysts mentioned in a be aware.

The corporate makes gene sequencing techniques, and curiosity is constructing within the long-read sequencing know-how Pacific Biosciences makes, the analysis be aware mentioned. 

“After years of stagnant development and numerous ranges of success in assembly timelines and targets, we consider PACB is on the verge of a income development inflection with the launch of the Revio (long-read) and Onso (short-read) devices,” the analysts wrote. 

The analysts estimate that, conservatively talking, if two in 5 Pacific Biosciences prospects purchase a Revio in 2024 and 2025, the income upside versus consensus could possibly be 6% for 2023, 14% for 2024, and 12% for 2025. The upside could possibly be much more if the shift to spending on long-read know-how positive aspects traction, as some consider.

“Surveyed customers count on to purchase nearly 3 Revios per lab on common” by to 2024, the analysts mentioned.

 



Source link –

Tags: BiosciencescitingCowengainsGrowthInvestingcomPacificpotentialsalesupgrade
admin

admin

Related Stories

UK regulator says it may clear Microsoft’s new Activision Blizzard takeover offer

UK regulator says it may clear Microsoft’s new Activision Blizzard takeover offer

by admin
September 22, 2023
0

Microsoft submitted a brand new proposal to U.Okay. regulators for the takeover of American sport writer Activision Blizzard after its...

Nio launches high-end smartphone for use with electric cars

Nio launches high-end smartphone for use with electric cars

by admin
September 21, 2023
0

Robert Approach/iStock Editorial through Getty Photos Chinese language electrical automobiles ((EVs)) maker Nio (NYSE:NIO) launched a high-end smartphone designed for...

billionaires’ crystal ball revelations By Crypto.news

billionaires’ crystal ball revelations By Crypto.news

by admin
September 20, 2023
0

© Reuters Bitcoin worth prediction 2024: billionaires’ crystal ball revelations Crypto.information - What do the billionaires and consultants forecast for...

Joe Biden urges world leaders to stop Ukraine from being ‘carved up’

by admin
September 19, 2023
0

Obtain free Battle in Ukraine updatesWe’ll ship you a myFT Every day Digest e mail rounding up the most recent...

Next Post
2 Large Cap Mutual Funds Have Given SIP Returns Of Nearly 31.80% In 3-Years

2 Large Cap Mutual Funds Have Given SIP Returns Of Nearly 31.80% In 3-Years

Leave a Reply Cancel reply

Your email address will not be published. Required fields are marked *

Stockguru

we brings premium business news and stock market news on this blog

No Result
View All Result
  • Home
  • Stock Market
  • Business
  • Econonmy
  • Investment

© 2022 Stockguru - Premium blog news & stock market Stockguru